BioCentury | Dec 27, 2016
Clinical News
BTI320: Ph II SG01 data
...and significantly reduced mean post-meal maximum glucose (p=0.03) vs. placebo. Boston Therapeutics markets BTI320 as SugarDown...
...glycemic health. Boston Therapeutics Inc. (OTCQB:BTHE), Lawrence, Mass. Product: BTI320 ( BTI-320 , SugarDown) (formerly PAZ320...
...blood glucose and HbA1c Status: Phase II data Milestone: NA Chris Lieu BTI-320 Boston Therapeutics Inc. Acid alpha glucosidase (GAA) BTI320 SugarDown...
...glycemic health. Boston Therapeutics Inc. (OTCQB:BTHE), Lawrence, Mass. Product: BTI320 ( BTI-320 , SugarDown) (formerly PAZ320...
...blood glucose and HbA1c Status: Phase II data Milestone: NA Chris Lieu BTI-320 Boston Therapeutics Inc. Acid alpha glucosidase (GAA) BTI320 SugarDown...